Platelets and HIV Reservoirs: A look at how platelets might harbor HIV in people living with HIV

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study examines the potential interaction between HIV reservoirs and platelets in people living with HIV who have had an undetectable viral load for more than two years. Blood samples are used to identify whether platelets carry HIV and to understand how this might influence latency and viral persistence. The approach does not involve an intervention beyond sampling and observational analysis. Results could help clarify whether platelets play a role in maintaining proviral DNA within reservoirs. The study is conducted at Tourcoing, France, led by Tourcoing Hospital with local collaboration only.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients living with HIV with an undetectable viral load for more than 2 years
* Beneficiary of a social security scheme or rightful claimant;
* Patients able to read and understand the information sheet;
* Having signed the consent form.

Exclusion Criteria:

* being unable to give free and informed consent;
* pregnant or breastfeeding woman;
* being under guardianship, curatorship, or a protection mandate;

Where it's running

• Centre Hospitalier de Tourcoing
  Tourcoing, France Recruiting

Study contacts

• Principal investigator: Olivier Robineau, MD, PhD — Centre Hospitalier de Tourcoing
• Study coordinator: Jean-Jacques VITAGLIANO, PhD
• Email: jjvitagliano@ch-tourcoing.fr
• Phone: +33320694280

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Project SHIELD 2.0: Police Education to Support Public Health in Kentucky

  Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Lexington, Kentucky · NCT07804121

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV

  This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.

  Recruiting Fenway Community Health · Boston, Massachusetts · NCT07762066

• HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters

  This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 7 other locations · NCT07757802

• Stigma-reducing program to help women who use drugs stay in HIV care

  This test checks whether a stigma-reduction program helps women living with HIV who use drugs stay engaged in HIV care in Ukraine.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Kyiv, Kyiv Oblast · NCT07751978

• Care Disengagement Prevention for People Living with HIV in Indonesia

  This intervention tests a stigma-reduction approach to help people living with HIV in Indonesia stay connected with HIV care.

  Recruiting University of California, Los Angeles · Depok, West Java · NCT07706634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.